Overview Financials News + Filings Key Docs Charts Ownership Insiders |
ProPhase Labs, Inc. (PRPH)
|
Add to portfolio |
|
|
Price: |
$7.69
| | Metrics |
OS: |
16.8
|
M
| |
|
|
Market cap: |
$130
|
M
| |
|
|
Net cash:
|
$9.1
|
M
| |
$0.54
|
per share
|
EV:
|
$120
|
M
| | | |
| | | | | |
TTM Valuation | | | |
EBITDA
|
|
| |
|
|
EBIT
|
|
| |
|
|
EPS |
| |
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
Revenues | 122.6 | 79.0 | 14.5 | 9.9 | 13.1 | 9.9 | 4.2 | 2.5 |
Revenue growth | 55.2% | 444.6% | 47.0% | -24.8% | 33.0% | 134.6% | 67.0% | -88.6% |
Cost of goods sold | 52.0 | 37.1 | 9.9 | 7.3 | 8.3 | 7.9 | 3.2 | 1.7 |
Gross profit | 70.7 | 42.0 | 4.6 | 2.6 | 4.8 | 1.9 | 1.0 | 0.8 |
Gross margin | 57.6% | 53.1% | 31.7% | 26.5% | 36.4% | 19.7% | 23.7% | 33.0% |
Sales and marketing | | | 1.3 | 1.0 | 1.1 | 0.7 | 1.7 | 0.3 |
Research and development | 0.7 | 0.5 | 0.6 | 0.3 | 0.4 | 0.4 | 0.4 | 0.3 |
General and administrative | 34.4 | 22.5 | 6.7 | 4.5 | 4.9 | 4.8 | 2.7 | 2.3 |
EBIT | 23.6 | 9.8 | -2.1 | -3.2 | -1.6 | -4.0 | -3.8 | -2.1 |
EBIT margin | 19.2% | 12.4% | -14.4% | -32.8% | -12.4% | -40.4% | -90.2% | -82.5% |
Pre-tax income | 22.9 | 5.3 | -2.3 | -3.1 | -1.5 | -3.7 | -4.0 | -2.1 |
Income taxes | 4.4 | -1.0 | 0.0 | 0.0 | 0.1 | -1.4 | -1.1 | 1.5 |
Tax rate | 19.4% | | | | | 38.8% | 28.4% | |
Earnings from continuing ops | 18.5 | 6.3 | -2.5 | -3.1 | -1.4 | -45.1 | -5.1 | -0.6 |
Earnings from discontinued ops | | | 0.2 | 0.0 | -0.2 | 42.8 | 1.1 | -1.5 |
Net income | 18.5 | 6.3 | -2.3 | -3.1 | -1.6 | -2.2 | -4.0 | -2.1 |
Net margin | 15.1% | 7.9% | -16.0% | -31.4% | -12.0% | -22.7% | -95.2% | -83.2% |
|
Diluted EPS | $0.99 | $0.34 | ($0.22) | ($0.27) | ($0.12) | ($2.87) | ($0.30) | ($0.04) |
Shares outstanding (diluted) | 18.7 | 18.4 | 11.6 | 11.6 | 11.4 | 15.7 | 17.1 | 16.4 |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|